#India #Mumbai #Lupin #Tenpoint #YUVEZZI

Lupin and Tenpoint Therapeutics form Strategic Partnership

In an exciting development for the pharmaceutical industry, Lupin Limited, a leading global company based in Mumbai, India, has announced a strategic alliance with Tenpoint Therapeutics. This partnership aims to commercialize YUVEZZI™, a groundbreaking ophthalmic solution, within the European Union and select countries including the United Kingdom, Switzerland, Norway, and Iceland.

Introduction to YUVEZZI™

YUVEZZI™ is recognized as the first and only once-daily, dual-agent eye drop specifically developed to manage presbyopia, a common vision condition that affects nearly 128 million adults in the United States and approximately 2 billion individuals globally. This innovative product works by combining two active ingredients: carbachol and brimonidine tartrate. Together, they help improve near vision in patients, making it a significant advancement in eye care.

Details of the Partnership

Under the terms of the licensing agreement, VISUfarma B.V., a wholly owned subsidiary of Lupin, has secured exclusive rights to oversee regulatory activities, marketing, sales, and distribution of YUVEZZI™ in the designated regions. This strategic move not only solidifies Lupin's commitment to expanding its footprint in the specialty care sector but also represents a vital step in enhancing access to effective treatments for presbyopia.

Vinita Gupta, the CEO of Lupin, expressed her enthusiasm about the collaboration, stating, "We are delighted to partner with Tenpoint Therapeutics to bring a novel ophthalmic therapy that advances our Specialty Care strategy. Our collaboration bolsters our eye care franchise and broadens our presence across key European markets."

Similarly, Henric Bjarke, CEO of Tenpoint Therapeutics, highlighted that the partnership is pivotal for making YUVEZZI™ available to millions of patients suffering from presbyopia. With Lupin's expansive commercial operations and VISUfarma's established record in ophthalmology, this partnership promises to better serve the needs of both patients and healthcare providers.

The Impact of YUVEZZI™ on Eye Care

As the only approved treatment of its kind in the market today, YUVEZZI™ stands out as an essential option for managing presbyopia. The eye drop promotes improved close-up vision by constricting the pupils, thus enhancing focal ability. The dual-action mechanism not only provides relief for those who struggle with vision clarity but also integrates seamlessly into daily routines.

Tenpoint is already pursuing the next steps for YUVEZZI™ in the U.S. markets following recent FDA approval and is planning to submit for regulatory recognition in the UK as well. The company is poised to expand its global reach with a strategy that includes local partnerships, ensuring that patients everywhere have access to this necessary treatment.

About Lupin

Lupin Limited is renowned globally, with operations in over 100 markets and a diverse product range that includes generics and specialty medicines. The company has established a robust market presence in core therapeutic areas, leading notably in the U.S. and India. With over 26,000 dedicated employees and 15 advanced manufacturing facilities, Lupin is committed to sustainable practices and continuous growth in the healthcare sector.

To learn more about Lupin's innovative products and services, interested parties can visit www.lupin.com.

About Tenpoint Therapeutics

Tenpoint Therapeutics Ltd. is a commercial-stage pharmaceutical company dedicated to advancing ocular health. Their focus on creating effective and innovative solutions for vision disorders like presbyopia has positioned them as a pioneer in the industry. More information about their endeavors can be found at their website.

This strategic partnership signals a promising future for presbyopia treatment across Europe, reflecting a growing commitment to improving patient care through innovative therapies.